PRTK - Paratek Pharmaceuticals: Undervalued Antibiotics Play With A Fighting Chance
Investment Thesis
Reviewing Paratek Pharmaceuticals (PRTK) - a commercial-stage biopharmaceutical company with 2 approved antibiotic products, Nuzyra and Seysara - I am inclined to believe that there is a reasonably strong case for investment.
The antibiotics market offers unfavourable market conditions at the present time, being overcrowded and not well-served by reimbursement opportunities. Developing and commercialising antibiotic treatments is generally considered to offer a poor return on investment owing to the end-products' short shelf life.
Paratek's current share price - $5.9 at the time of writing - reflects these conditions. But thanks to